310 related articles for article (PubMed ID: 8254497)
1. Novel formulation strategies for improving oral bioavailability of drugs with poor membrane permeation or presystemic metabolism.
Aungst BJ
J Pharm Sci; 1993 Oct; 82(10):979-87. PubMed ID: 8254497
[TBL] [Abstract][Full Text] [Related]
2. Diverse approaches for the enhancement of oral drug bioavailability.
Fasinu P; Pillay V; Ndesendo VM; du Toit LC; Choonara YE
Biopharm Drug Dispos; 2011 May; 32(4):185-209. PubMed ID: 21480294
[TBL] [Abstract][Full Text] [Related]
3. Nanocarriers: a general strategy for enhancement of oral bioavailability of poorly absorbed or pre-systemically metabolized drugs.
Cai Z; Wang Y; Zhu LJ; Liu ZQ
Curr Drug Metab; 2010 Feb; 11(2):197-207. PubMed ID: 20384585
[TBL] [Abstract][Full Text] [Related]
4. Amorphous solid dispersion of berberine with absorption enhancer demonstrates a remarkable hypoglycemic effect via improving its bioavailability.
Zhaojie M; Ming Z; Shengnan W; Xiaojia B; Hatch GM; Jingkai G; Li C
Int J Pharm; 2014 Jun; 467(1-2):50-9. PubMed ID: 24607213
[TBL] [Abstract][Full Text] [Related]
5. Bioavailability enhancement strategies: basics, formulation approaches and regulatory considerations.
Beg S; Swain S; Rizwan M; Irfanuddin M; Malini DS
Curr Drug Deliv; 2011 Nov; 8(6):691-702. PubMed ID: 21864253
[TBL] [Abstract][Full Text] [Related]
6. Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor.
Hauss DJ; Fogal SE; Ficorilli JV; Price CA; Roy T; Jayaraj AA; Keirns JJ
J Pharm Sci; 1998 Feb; 87(2):164-9. PubMed ID: 9519148
[TBL] [Abstract][Full Text] [Related]
7. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
[TBL] [Abstract][Full Text] [Related]
8. Nano-based drug delivery system enhances the oral absorption of lipophilic drugs with extensive presystemic metabolism.
Zhang Z; Gao F; Jiang S; Ma L; Li Y
Curr Drug Metab; 2012 Oct; 13(8):1110-8. PubMed ID: 22380010
[TBL] [Abstract][Full Text] [Related]
9. Using peptides to increase transport across the intestinal barrier.
Sánchez-Navarro M; Garcia J; Giralt E; Teixidó M
Adv Drug Deliv Rev; 2016 Nov; 106(Pt B):355-366. PubMed ID: 27155131
[TBL] [Abstract][Full Text] [Related]
10. Polymeric micelles for oral drug delivery.
Gaucher G; Satturwar P; Jones MC; Furtos A; Leroux JC
Eur J Pharm Biopharm; 2010 Oct; 76(2):147-58. PubMed ID: 20600891
[TBL] [Abstract][Full Text] [Related]
11. Integrating drug permeability with dissolution profile to develop IVIVC.
Takano R; Kataoka M; Yamashita S
Biopharm Drug Dispos; 2012 Oct; 33(7):354-65. PubMed ID: 22581486
[TBL] [Abstract][Full Text] [Related]
12. [Oral bioavailability and drug/carrier particulate systems].
Wawrezinieck A; Péan JM; Wüthrich P; Benoit JP
Med Sci (Paris); 2008; 24(6-7):659-64. PubMed ID: 18601886
[TBL] [Abstract][Full Text] [Related]
13. Presystemic metabolism of orally administered peptide drugs and strategies to overcome it.
Bernkop-Schnürch A; Schmitz T
Curr Drug Metab; 2007 Jun; 8(5):509-17. PubMed ID: 17584022
[TBL] [Abstract][Full Text] [Related]
14. The utility of cyclodextrins for enhancing oral bioavailability.
Carrier RL; Miller LA; Ahmed I
J Control Release; 2007 Nov; 123(2):78-99. PubMed ID: 17888540
[TBL] [Abstract][Full Text] [Related]
15. Strategies to improve oral drug bioavailability.
Gomez-Orellana I
Expert Opin Drug Deliv; 2005 May; 2(3):419-33. PubMed ID: 16296764
[TBL] [Abstract][Full Text] [Related]
16. Ligand-mediated active targeting for enhanced oral absorption.
Zhang X; Wu W
Drug Discov Today; 2014 Jul; 19(7):898-904. PubMed ID: 24631680
[TBL] [Abstract][Full Text] [Related]
17. Modification of physicochemical characteristics of active pharmaceutical ingredients and application of supersaturatable dosage forms for improving bioavailability of poorly absorbed drugs.
Kawakami K
Adv Drug Deliv Rev; 2012 May; 64(6):480-95. PubMed ID: 22265844
[TBL] [Abstract][Full Text] [Related]
18. Optimizing Oral Bioavailability in Drug Discovery: An Overview of Design and Testing Strategies and Formulation Options.
Aungst BJ
J Pharm Sci; 2017 Apr; 106(4):921-929. PubMed ID: 27986598
[TBL] [Abstract][Full Text] [Related]
19. Drug dissolution: significance of physicochemical properties and physiological conditions.
Jambhekar SS; Breen PJ
Drug Discov Today; 2013 Dec; 18(23-24):1173-84. PubMed ID: 24042023
[TBL] [Abstract][Full Text] [Related]
20. Nanocarriers protecting toward an intestinal pre-uptake metabolism.
Suchaoin W; Bernkop-Schnürch A
Nanomedicine (Lond); 2017 Feb; 12(3):255-269. PubMed ID: 28093952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
